Hong Kong's Li Ka-shing appears in person for first time since Hutchison ports deal
Li Ka-shing has made his first in-person public appearance since controversy erupted over his conglomerate's sale of its overseas ports to a consortium led by American investment firm BlackRock amid the US-China trade war, a deal that has drawn Beijing's ire.
Advertisement
The founder of
CK Hutchison Holdings visited Hong Kong Sanatorium & Hospital (HKSH) in Happy Valley on Tuesday to observe a demonstration of a cutting-edge, non-invasive device donated by the Li Ka Shing Foundation for treating liver cancer.
'[The hospital] providing this option is definitely great news,' Li said.
The 'Histotripsy 2.0' system was delivered to the hospital this month.
The 96-year-old tycoon, nicknamed 'Superman' for his business acumen and influence, appeared energetic and joyful, grinning while shaking hands with Walton Li Wai-tat, CEO of HKSH Medical Group and medical superintendent of the hospital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
an hour ago
- South China Morning Post
Why Lockheed Martin's Philippine R&D hub will be on China's radar
Lockheed Martin is set to establish an R&D facility in Manila in partnership with a major Philippine university, in a move analysts say will both strengthen the nation's technological foundations and enmesh it further into Washington's regional security framework. The American defence giant announced on Tuesday a collaboration with Southern Methodist University (SMU) aimed at boosting innovation, developing advanced technologies and nurturing local talent in partnership with Philippine academic and industrial institutions. The initiative forms part of Lockheed Martin's F-16 Block 70 proposal for the Philippine military's multi-role fighter programme. Jess Koloini, business development lead for Lockheed Martin's F-16 programme, described the partnership as an investment in 'new capabilities and intellectual properties' through close cooperation with the Philippines ' leading universities and companies. 'This partnership will not only support the country's 'self-reliant defence posture', but also create a lasting impact on the Filipino workforce, driving economic growth and prosperity,' he said. Visitors at Lockheed Martin's exhibition stall during the Aero India air show on February 12. Photo: EPA-EFE Under the agreement, SMU's Centre for Digital and Human-Augmented Manufacturing and its Deason Innovation Gym will help strengthen Philippine research and development capacity in digital modelling, simulations, robotics, automation, artificial intelligence and virtual and augmented reality.
South China Morning Post
2 hours ago
- South China Morning Post
Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group, two of China's largest drug makers, are expected to report significantly improved profits, buoyed by novel drug roll-outs and revenue from technology licensing. On August 21, Hengrui, China's largest drug maker by market value, is expected to say its net profit for the first half rose 40 per cent from a year earlier to 4.1 billion yuan (US$570.8 million), with revenue up 9 per cent to 15.7 billion yuan, according to analysts' consensus estimates from Bloomberg. For all of 2025, the company's profit is expected to improve 28 per cent to 8.1 billion yuan. The Shanghai-listed company went public in Hong Kong in May, raising HK$9.9 billion (US$1.26 billion). The ramp-up of novel drug sales is a key driver of the company's profit growth, as past research and development efforts paid off and reduced its reliance on less lucrative generics, analysts said. 'The launches of these innovative drugs will further improve Hengrui's revenue structure and shrink the role of generic drugs in its business,' Huayuan Securities analyst Liu Chuang said in a July 29 report. According to a recent report from Guotai Haitong Securities, generics accounted for 43 per cent of Hengrui's revenue last year, down from 62 per cent in 2022. That figure was expected to fall to 23 per cent in 2027. After a decade of policy reforms that raised the quality of generics and cut red tape for innovative drug approvals, Beijing has urged the nation's pharmaceutical firms to invest in novel drug development to raise the industry's global competitiveness.
South China Morning Post
2 hours ago
- South China Morning Post
Reclassified commercial property loans are no cause for panic
Call it the three stages of commercial property loan grief. It's not the kind of technical metrics that usually get newspaper readers all hot and bothered. But since the local market has been going through a prolonged slump, people are getting an education in commercial real estate finance. The latest news has been the exposure of HSBC, the city's largest lender, to the sector. Almost three-quarters of its commercial property loans were supposedly flashing warning signals by the end of June. HSBC reportedly accounts for US$32 billion of the city's total US$234 billion in such loans. More loans are being reclassified at higher stages of credit risk, such as at stage 2 for significantly increased risk and stage 3 for signs of impairment. But if that is indicative of the city's overall loanbook, the overall classified loan ratio – a key measure of borrowings considered substandard, doubtful or at loss – should worsen. But that's not the case. On the surface, those headline numbers certainly sound alarming, with hints of a property sector collapse and a banking crisis. In context, though, there is less to this than meets the eye. About 73 per cent of HSBC's commercial real estate loan book was classified as 'satisfactory or stronger' in June, compared with 75 per cent in December. Stage 2 classification shows a deterioration in credit quality, unavoidable in a gloomy market. But rather than being indicative of default, it is a pre-emptive classification, or early warning. It calls for caution, not alarm. About 80 per cent of those cases have a loan-to-value ratio of less than 70 per cent, meaning they are well within the safe loan parameters, thus limiting the bank's exposure. According to the Hong Kong Monetary Authority (HKMA), the local banking industry's classified loan ratio was 1.97 per cent at the end of the second quarter, little changed from 1.98 per cent in the first quarter. The long-term average is around 2 per cent. At its worst, the ratio was 7.4 per cent in 1999, following the Asian financial crisis.
